Results 301 to 310 of about 22,236,668 (323)
Some of the next articles are maybe not open access.
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Oncology (Williston Park, N.Y.), 2014In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin. These are commonly used in the treatment of relapsed/refractory (
openaire +1 more source
Journal of Geriatric Oncology
Limited tools exist to specifically predict the risk of chemotherapy toxicity and related events in older individuals with gastrointestinal (GI) cancers.We evaluated patients aged ≥60 years with GI cancers who underwent a comprehensive geriatric assessment comprising demographic, cancer variables, and geriatric domains (function, comorbidities ...
Vallish, Shenoy +21 more
openaire +2 more sources
Limited tools exist to specifically predict the risk of chemotherapy toxicity and related events in older individuals with gastrointestinal (GI) cancers.We evaluated patients aged ≥60 years with GI cancers who underwent a comprehensive geriatric assessment comprising demographic, cancer variables, and geriatric domains (function, comorbidities ...
Vallish, Shenoy +21 more
openaire +2 more sources
[Treatment-related adverse events associated with antibody drug conjugate in breast cancer].
Bulletin du cancerTherapeutic options for breast cancer have recently been enriched by new antibody-drug conjugates (ADC), which are now being utilized across all known molecular subtypes. ADCs represent a groundbreaking class of therapies that combine a cytotoxic agent with a monoclonal antibody via a combination molecule (linker).
Bérénice, Collineau +3 more
openaire +1 more source
Trends in Adverse Event Rates in Hospitalized Patients, 2010-2019
JAMA - Journal of the American Medical Association, 2022Mark L Metersky +2 more
exaly
Lung Cancer Radiation May Increase the Risk of Major Adverse Cardiac Events
Ca-A Cancer Journal for Clinicians, 2019Mike Fillon
exaly
Treatment-related adverse events of antibody-drug conjugates: review of clinical toxicity
Reactions Weekly, 2022openaire +1 more source

